The levels of 8S-lipoxygenase (8S-LOX) expression and of its arachidonic acid metabolite, 8-hydroxyeicosatetraenoic acid (8-HETE), are highly elevated in the early stages of mouse skin carcinogenesis. On the other hand, several reports showing that 8-HETE is also closely associated with keratinocyte differentiation raise a question concerning the role of 8S-LOX/8-HETE in skin carcinogenesis. To address that question, here we conducted a series of gain-of-function studies. Skin targeted loricrin 8S-LOX/C57BL/6J transgenic mice showed a more differentiated epidermal phenotype as well as a 64% reduced papilloma development in a two-stage skin carcinogenesis protocol. Forced expression of 8S-LOX in MT1/2 cells, a murine papilloma cell line, also caused a more differentiated appearance as well as keratin 1 expression. Overexpression of 8S-LOX in CH72 cells, a murine carcinoma cell line, inhibited cell proliferation by 30% in vitro and by 86% in in vivo xenografts. Exogenous addition of 5 lM 8-HETE to CH72 cells caused cell cycle arrest at the G1 phase. Finally, immunohistochemical analyses showed 8S-LOX protein expression was strictly confined to the differentiated compartment of mouse skin and throughout tumorigenesis. Collectively, these data suggest that 8S-LOX plays a role as a prodifferentiating, antitumorigenic, and tumor suppressing gene in mouse skin carcinogenesis.
Introduction
Following a variety of stimuli such as wounding, growth factors, and hormones, arachidonic acid (AA, 5, 8, 11, 14 eicosatetraenoic acid, 20 : 4, nÀ6 ) is promptly released from cell membrane phospholipids by the action of phospholipases and is metabolized to bioactive lipid mediators by cyclooxygenases (COXs) and lipoxygenases (LOXs). These metabolites, including prostaglandins (PGs), thromboxanes (from COXs), leukotrienes, and hydroxyeicosatetraenoic acids (HETEs) (from LOXs), are known to execute a number of physiologically important functions (Ruzicka and Printz, 1984) . The AA cascade is tightly regulated in the cell and aberrant metabolism has been implicated in the pathogenesis of many human diseases such as cancer Warner and Mitchell, 2004) .
A large body of evidence has shown an excessively activated COX pathway in a variety of human cancers (Fosslien, 2000) . Protumorigenic roles of PGs have been documented (Fosslien, 2000) and moreover, some of the COX-specific inhibitors are already in clinical use for the prevention of colon cancer (Steinbach et al., 2000) . On the other hand, research on the role of LOXs in tumorigenesis has lagged behind that of the COXs. This is partly because: (1) most of the LOX isozymes have relatively recently been cloned compared to the COXs; (2) LOXs are a more complex system in terms of the number of isozymes, tissue specificity, as well as substrate usage than the COXs; and (3) only a few specific LOX inhibitors are available. However, reports suggesting that LOXs and their metabolites also exert a substantial impact on the development of animal as well as human cancers have gradually increased (Steele et al., 1999; Shureiqi and Lippman, 2001; Fischer and Klein, 2004) .
LOXs are a family of dioxygenases that insert an oxygen molecule onto specific carbons of polyunsaturated fatty acids in a regio-and stereo-selective manner (Prigge et al., 1997) . So far, at least six different isozymes have been identified in mammals and the enzymes convert AA to 5-, 8-, 12-or 15-hydroperoxyeicosatetraenoic acid and convert linoleic acid (LA) to 9-or 13-hydroperoxyoctadecadienoic acid (Brash, 1999) . These hydroperoxy derivatives are subsequently reduced to the corresponding HETE and hydroxyoctadecadienoic acid (HODE) by glutathione peroxidase. Unlike an excessively activated COX pathway in many of human cancers, a specific LOX pathway is either upor downregulated depending on tumor type. This is probably because while COX metabolites mainly exert a procarcinogenic role, LOX metabolites play a role as either pro-or anticarcinogenic lipid mediators in a metabolite-and tumor type-specific manner . For example, 13-HODE induces apoptosis in human colon cancer cells (Shureiqi et al., 2003) or in esophageal cancer cells , whereas it accelerates proliferation of human prostate cancer cells (Kelavkar et al., 2001) . AA metabolites of 5S-LOX, 5-HETE and leukotrienes, are mainly procarcinogenic mediators and stimulate the proliferation of cancer cells via inflammation (DuBois, 2003) . In the case of 12-HETE, it contributes to tumor growth and malignancy by increasing angiogenesis (Nie et al., 1998) and metastasis (Tang and Honn, 1994) . On the other hand, 15-HETE has been shown to be a critical negative cell cycle regulator in human prostate cancer (Tang et al., 2002) . Therefore, clear understanding of the roles of each LOX and its metabolite is indispensable to further understanding their contribution to carcinogenesis as well as to their potential as preventive or therapeutic targets.
One of the LOXs for which the role in tumorigenesis has not yet been clearly elucidated is 8S-lipoxygenase (8S-LOX). It is a murine homolog of human 15S-LOX-2 and metabolizes AA and LA to 8-HETE and 9-HODE, respectively (Gschwendt et al., 1986; Fu¨rsten-berger et al., 1991; Jisaka et al., 1997; Bu¨rger et al., 1999) . However, it uses AA as a preferred substrate. In normal mouse skin, the level of 8S-LOX expression as well as 8-HETE is nearly undetectable. However, the level is highly elevated after a single topical treatment of 12-O-tetradecanoylphorbol-13-acetate (TPA) (Gschwendt et al., 1986; Fu¨rstenberger et al., 1991; Jisaka et al., 1997) and is further increased in papillomas (Bu¨rger et al., 1999; Nair et al., 2000) . In carcinomas, 8S-LOX expression as well as 8-HETE production is back to the level of normal skin (Bu¨rger et al., 1999; Nair et al., 2000) . In support of a relationship between 8S-LOX activity and skin tumor development, a good correlation between the level of 8-HETE and the level of promutagenic etheno-DNA adduct formation in mouse skin tumors has been reported (Nair et al., 2000) . Additionally, a clastogenic activity of 8-HETE has also been demonstrated (Bu¨rger et al., 1999) . Since accumulation of chromosomal alterations accompanies malignant conversion of papillomas to carcinomas, Fu¨rstenberger et al. (2002) suggested that 8-HETE could be an endogenous factor that is responsible for the genomic instability observed in the premalignant lesions. On the other hand, we have recently reported that 8-HETE has the ability to induce keratinocyte differentiation through a selective activation of peroxisome proliferator-activated receptor (PPAR)-a in primary keratinocytes . In fact, skin targeted 8S-LOX transgenic mice showed a highly differentiated and keratinized epidermal phenotype . Although a high degree of differentiation can stimulate keratinocyte proliferation in skin through a compensatory mechanism, considering that differentiation in general inversely correlates with the malignancy of tumors, the ultimate consequence of 8-HETE production during mouse skin carcinogenesis remained to be clarified. To that end, we conducted a series of gain-of-function studies on 8S-LOX/8-HETE in vitro and in vivo. Our results show that an enforced increase of 8-HETE production in normal and tumorigenic keratinocytes resulted in increased differentiation and cell cycle arrest of the keratinocytes, and a reduced skin tumor response to an initiation-promotion protocol.
Results

Generation of 8S-LOX/C57BL/6J transgenic mice
To determine the role of 8S-LOX/8-HETE in mouse skin carcinogenesis, we generated skin targeted C57BL/ 6J transgenic mice overexpressing the 8S-LOX gene under the control of loricrin promoter. Of note is that unlike in the skin of TPA tumor promotion-sensitive strains (SSIN, CD-1, and NMRI), 8S-LOX expression is only very weakly induced by TPA treatment in the skin of promotion-resistant C57BL/6J mice (Fischer et al., 1988; Bu¨rger et al., 1999) . Figure 1a shows 8S-LOX mRNA expression in wild-type and in 8S-LOX/C57BL/ 6J transgenic mice. A slight induction of 8S-LOX mRNA by TPA treatment was detected in wild-type mice, whereas strong and constitutive expression of 8S-LOX mRNA was detected in transgenic mouse skin. This transgene expression was not increased much further by TPA treatment. Notably, 8S-LOX transgene message was detected as a shorter fragment than the TPA-induced endogenous 8S-LOX mRNA (3.2 kb) in wild-type mice. This is probably because the transgene does not contain the entire 3 0 -untranslated region. We also detected strong 8S-LOX protein expression from the transgenic mouse skin (Figure 1b ) and we confirmed that the protein has enzyme activity by liquid chromatography/tandem mass spectrometry (LC/MS/MS) Figure 1 Transgene expression in 8S-LOX/C57BL/6J transgenic mice. (a) Northern blot of total RNA (10 mg) isolated from wildtype and 8S-LOX transgenic mouse skin treated for 9 h with acetone (À) or TPA (4 mg; þ ). The blot was hybridized with a radiolabeled 8S-LOX cDNA probe, stripped, and rehybridized with a radiolabeled GAPDH cDNA probe to control for loading. Each lane represents RNA from individual mice. (b) Western blot of total protein (30 mg) isolated from wild-type and 8S-LOX transgenic mouse skin treated for 9 h with acetone or TPA (4 mg).
The blot was hybridized with antisera against 8S-LOX, stripped, and rehybridized with a b-actin antibody to control for loading analysis ( Table 1 ). The transgenic mouse skin contained threefold more 8-HETE compared to wild-type skin (Table 1) . However, the level of 9-HODE, an LA metabolite of 8S-LOX, was not different between transgenic and wild-type mice (Table 1) .
Characterization of 8S-LOX/C57BL/6J transgenic mice
Overexpression of 8S-LOX in C57BL/6J mouse skin did not create a macroscopic skin phenotype. However, histological analysis showed that the epidermis of 8S-LOX transgenic mice was much thinner and more stretched than that of wild-type mice (Figure 2a) . Moreover, aberrant keratin 1 (K1) expression was detected in some of the basal cells and stronger K1 expression was detected in the suprabasal layers of transgenic mouse skin compared to wild-type mice (Figure 2b) . Interestingly, when the 8S-LOX transgenic and the wild-type mice were subjected to the two-stage skin carcinogenesis protocol, shaved dorsal skin hair did not grow back in wild-type mice, whereas it completely grew back in 8S-LOX transgenic mice after 8 weeks of multiple TPA treatments (data not shown). Since hair is another differentiated structure of the epidermis, we speculate that increased hair growth also arises from enhanced differentiation stimulated by 8S-LOX. In fact, it has been reported that 8S-LOX expression as well as enzyme activity are strongly induced by TPA treatment in neonatal mouse skin around the time when hair development begins (Gschwendt et al., 1986; Jisaka et al., 1997) . Despite the observed phenotypic characteristics of increased differentiation in transgenic mice, the rate of basal and TPA-induced cell proliferation in the interfollicular epidermis was not significantly different between wild-type and 8S-LOX transgenic mice (Figure 2c ).
Two-stage skin carcinogenesis study
From previous experience, we knew that twice a week treatment with TPA would not induce tumor formation in C57BL/6J mice (Fischer et al., 1989) . Nevertheless, we used this protocol to determine whether 8S-LOX transgene expression could restore TPA promotion sensitivity to the C57BL/6J mice. However, no tumors arose in either wild-type or transgenic mice with this protocol (Figure 3a) . We therefore switched the protocol from twice a week to five times a week TPA treatment at 15 weeks of promotion and examined tumor formation. This protocol was previously shown to elicit tumors in C57BL/6J mice (Fischer et al., 1989) . As shown in Figure 3a , both wild-type and transgenic mice started to develop papillomas at 4 weeks from the point of protocol switch (i.e. 19 weeks of promotion). Interestingly, tumor multiplicity (number of papillomas/mouse) kept increasing in wild-type, whereas it reached an early plateau in transgenic mice (average 3.5 papillomas/ mice). At 29 weeks of promotion, tumor multiplicity in the 8S-LOX transgenic mice was 64% lower than that of wild-type mice. To verify these results, we conducted another independent tumor experiment and similar results were obtained (data not shown). On the other hand, there was no significant difference in tumor incidence or carcinoma formation between wild-type and transgenic mice ( Figure 3b and data not shown).
Enforced 8S-LOX transgene expression in MT1/2 papilloma cells
To determine the role of 8S-LOX/8-HETE in skin tumor cells, an expression vector with 8S-LOX cDNA was transfected into MT1/2 murine papilloma cells and the effect of 8S-LOX expression on proliferation and differentiation was examined. Of note, although MT1/2 cells form skin papillomas when grafted onto nude mice (Conti et al., 1988a) , the cells do not express the endogenous 8S-LOX gene, similar to that observed in other established murine keratinocyte cell lines. In all, 12 and 23 individual neomycin-resistant clones from the vector control and the 8S-LOX-transfected MT1/2 cells, respectively, were selected and screened for expression of the 8S-LOX message by Northern analysis. Five 8S-LOX-transfected clones expressed various levels of 8S-LOX, whereas none of the clones selected from the vector control transfectants expressed 8S-LOX ( Figure 4a and data not shown). Interestingly, regardless of the level of 8S-LOX expression, most of the 8S-LOXtransfected cells showed a much more flattened cell morphology compared to the parental MT1/2 or MT1/ 2-neo cells (Figure 4b ). Since the observed appearance of cells is a phenotypic characteristic of differentiated keratinocytes, we then tried to detect K1 expression in MT1/2-8S-LOX or MT1/2-neo clones. Strong or weak K1 expression was clearly detected throughout the 8S-LOX transfectants but not in the any of MT1/2-neo clones ( Figure 4a and data not shown). Notably, however, the level of K1 expression was not exactly correlated with the level of 8S-LOX expression among the MT1/2-8S-LOX clones. We speculate that if expressed 8S-LOX has enzyme activity, there may be a threshold level of 8-HETE that is required to induce K1 expression. Despite these interesting observations, however, we could not proceed further with these clones because the MT1/2-8S-LOX clones started to lose 8S-LOX transgene expression as well as their differentiated cell morphology after two to three passages. We 
Effects of exogenous 8-HETE on the proliferation of CH72 carcinoma cells
We then wanted to determine whether 8-HETE could inhibit carcinoma cell proliferation as well. CH72 murine squamous carcinoma cells were treated with 1, 5, and 10 mM of 8-HETE and the effect of exogenous 8-HETE on cell proliferation was determined. As shown in Figure 5a , 1 mM of 8-HETE did not significantly affect Anticarcinogenic role of murine 8S-LOX E Kim et al the proliferation of CH72 cells compared to the vehicle control cells. However, 5 and 10 mM of 8-HETE significantly inhibited cell proliferation by 50 and 70%, respectively, compared to the vehicle control cells at 72 h. We confirmed that this 8-HETE-mediated inhibition was not due to increased apoptosis of the cells but rather due to cell cycle arrest at G1 phase by flow cytometry (Figure 5b and c).
Generation of a CH72 carcinoma cell line constitutively expressing 8S-LOX
To assess the possible inhibitory effect of 8S-LOX/8-HETE on CH72 carcinoma cell proliferation in vivo, we next generated CH72-8S-LOX stable clones. Figure 6a shows various levels of 8S-LOX mRNA expression in the CH72-8S-LOX stable clones and the absence of 8S-LOX expression in the CH72-neo clones. We further screened these clones on the basis of 8S-LOX protein expression as well as enzyme activity and chose two vector control (CH72-neo #1 and #2) and two 8S-LOXexpressing clones (CH72-8S-LOX #7 and #9) for further studies. The CH72-8S-LOX #7 and #9 clones clearly expressed 8S-LOX protein ( Figure 6b ) and converted exogenously added AA to nine-and 13-fold more 8-HETE, respectively, than the CH72-neo clones ( Figure 6c ). We confirmed that the 8S-LOX transgene Anticarcinogenic role of murine 8S-LOX E Kim et al expression in the CH72-8S-LOX #7 and #9 clones was maintained at least up to passage 10 (data not shown).
Characterization of CH72-8S-LOX stable clones in vitro
Unlike MT1/2-8S-LOX stable clones, CH72-8S-LOX clones did not express K1 and also did not exhibit a differentiated cell morphology (data not shown). However, we noticed that CH72-8S-LOX #7 and #9 clones looked much more irregular as well as more stressed and in addition, cell proliferation was also poorer than the CH72-neo clones (data not shown). Therefore, the rate of cell proliferation over 5 days was compared between CH72-8S-LOX #7 and #9 clones and CH72-neo #2 clones by determining cell numbers. Interestingly, 8S-LOX#7 and #9 clones proliferated similarly to the CH72-neo #2 clone when the cells were in a subconfluent state. However, the number of cells/dish of the 8S-LOX clones was significantly reduced (approximately 30%) compared to the neo clone as the cells became more confluent (Figure 7a ). These data suggest a possibility of contact inhibition or senescence conferred by 8S-LOX expression in CH72 cells. Genomic instability in CH72-8S-LOX and -neo stable clones was also assessed by inter-simple sequence repeat (SSR) PCR; however, no difference was detected between 8S-LOX and neo clones (data not shown).
Xenograft studies
CH72-neo #1, -neo #2, -8S-LOX #7, and -8S-LOX #9 clones were then injected subcutaneously into athymic nude mice and tumor formation was examined for 9 weeks. As shown in Figure 7b , xenografts of all of the clones resulted in tumors. However, the tumors arising from the 8S-LOX clones were slower growing and were much smaller (mean volume7s.d.: 0.0570.04 vs 0.3570.06 cm 3 for 8S-LOX and neo clones, respectively) compared to the tumors arising from the CH72-neo clones. Since slow and poor tumor growth could be due to either increased apoptosis or decreased proliferation of tumor cells, 5-bromo-2 0 -deoxyuridine (BrdU) was injected into all of the mice before killing and tumor sections were immunostained for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) or BrdU. There was no difference in the number of TUNEL-positive cells between the tumors derived from either 8S-LOX or neo clones (data not shown). However, much lower BrdU incorporation was detected in 8S-LOX xenografts compared with the neo xenografts (mean BrdU-positive The tumor sections were also stained with antibody against 8S-LOX or K1; however, none of the tumors expressed significant amounts of 8S-LOX or K1 protein (data not shown). We also compared the genomic instability of neo-and 8S-LOX xenografts by inter-SSR PCR; however, we could not detect any differences between them (data not shown).
Localization of 8S-LOX
It has been reported that 8S-LOX protein expression is restricted to the differentiated keratinocyte compartment in normal and TPA-treated mouse skin (Jisaka et al., 1997) . To localize 8S-LOX expression in the course of skin tumor development, tissue sections from normal, TPA-treated skin, papillomas, and carcinomas from wild-type C57BL/6J mice were immunostained for 8S-LOX, as well as for K1 and the proliferation marker Ki67. Interestingly, proliferating, undifferentiated cells were negative for 8S-LOX staining, whereas differentiated keratinocytes were positive for 8S-LOX staining even in the tumors (Figure 8 ). This observation suggests that 8S-LOX is closely associated with keratinocyte differentiation and that loss of 8S-LOX expression accompanies loss of differentiation during progression to malignant tumors.
Discussion
Despite much evidence suggesting a procarcinogenic activity for 8S-LOX/8-HETE in mouse keratinocytes (Gschwendt et al., 1986; Bu¨rger et al., 1999; Nair et al., 2000) , here we provide strong evidence that 8S-LOX/8-HETE is in fact playing an anticarcinogenic role in mouse skin carcinogenesis. C57BL/6J mice develop only mild inflammatory and hyperplastic responses to TPA treatment and are resistant to TPA tumor promotion using the classical twice weekly protocol (Sisskin et al., 1982; Fischer et al., 1988; Naito and DiGiovanni, 1989) . Since TPA-induced inflammation as well as hyperplasia are events most closely associated with TPA tumor promotion (Slaga, 1984; DiGiovanni, 1992) , the absence of these events after chronic TPA treatment has been thought to be one of the critical reasons for the TPA tumor promotion resistance in C57BL/6J mice. In fact, enforced expression of ornithine decarboxylase in C57BL/6J mouse skin induced hyperplasia of the epidermis and converted C57BL/6J from resistant to sensitive to TPA-induced tumor promotion (Guo et al., 1999) . On the other hand, since AA metabolites have also been shown to play an important role in inflammation as well as hyperplasia in mouse skin (Verma et al., 1980; Fischer et al., 1982; Nakadate et al., 1982; Fischer et al., 1987) , the profiles of major COX and LOX products after TPA treatment were compared between SSIN and C57BL/6J mouse skin. The only significant difference found in the products was 8-HETE, which was highly increased by TPA in SSIN but not in C57BL/6J skin (Fischer et al., 1988) . For this reason, enforced production of 8-HETE in C57BL/6J mouse skin was expected to increase the hyperplastic response and sensitivity to tumor promotion by TPA treatment. However, 8S-LOX/C57BL/6J transgenic mice instead exhibited several indications of increased differentiation, including thinner epidermis, Figure 7 Proliferation of CH72-8S-LOX stable clones in vitro and in vivo. (a) In vitro proliferation of CH72-neo and CH72-8S-LOX stable clones. Cells were plated at 5 Â 10 4 cells/60 mm dish and media changed every two days. At days 1, 3, and 5 after plating, the cells were trypsinized and the total cell number was calculated by hemacytometer. The data are the mean7s.d. of at least three independent experiments each carried out in triplicate. Note that the total cell number of 8S-LOX #7 and #9 clones at day 5 was significantly different (Po0.05, unpaired t-test) from that of pCIneo #2 clone. (b) In vivo growth of xenograft tumors. Cultured CH72-8S-LOX (#7 and #9) and CH72-neo (#1 and #2) stable clones (5 Â 10 6 cells/site) were subcutaneously injected into four different sites (two shoulders and two flanks) of two female athymic nude mice each. Tumor diameters (length and width) were measured once a week and tumor volume was estimated as 1 2 (length Â width 2 ). The data are representative of two independent experiments. Average tumor volumes of 8S-LOX clones #7 and #9 were significantly smaller (Po0.05, two-way analysis of variance) than that of pCIneo #1 and #2 clones Anticarcinogenic role of murine 8S-LOX E Kim et al faster hair growth and K1 expression in basal as well as suprabasal cells. Significantly, they were even more resistant to TPA tumor promotion. Moreover, the fast regrowth of shaved hair after multiple TPA treatments in the transgenic mice suggests an anti-inflammatory effect of 8-HETE as well, since hair loss has been reported as one of the secondary effects elicited from TPA-induced inflammation (Mahe´, 1998; Ru¨ckert et al., 2000) . A number of reports have shown anti-inflammatory properties of PPARa coupled with antiproliferative and prodifferentiating effects in keratinocytes (Hanley et al., 1998; Ko¨mu¨ves et al., 2000; Thuillier et al., 2000; Sheu et al., 2002) . Considering 8-HETE is the most potent endogenous ligand of PPARa (Yu et al., 1995; Muga et al., 2000) , it is reasonable to speculate that the observed hair phenotype, increased differentiation, and reduced tumorigenesis in the 8S-LOX transgenic mice resulted from a PPARa-mediated effect of 8-HETE in the keratinocytes. Of note is that despite all these anticarcinogenic features in 8S-LOX transgenic mice, basal cell proliferation was not affected. A possible explanation is that the total number of proliferating cells Figure 8 8S-LOX expression in mouse skin and in skin tumors. Tissue sections of (a) normal skin, (b) TPA-treated skin (4 mg of TPA for 24 h treatment), and (c) a papilloma from wild-type C57BL/6J mice and (d) a carcinoma from FVB mouse were immunostained with antisera against 8S-LOX. Since none of the C57BL/6J mice developed carcinomas in our two-stage carcinogenesis protocol, carcinomas from similar skin carcinogenesis protocol in FVB mice were used for this experiment. Serial sections from the same papilloma as in (c) were also immunostained with antibodies against (e) K1 (a marker for differentiation) and (f) Ki67 (a marker for proliferation). All sections were photographed at Â 200 and the inserts were photographed at Â 1000. The black-boxed area in each photograph indicates where the insert was taken from. Data are representative of at least three independent tissues Anticarcinogenic role of murine 8S-LOX E Kim et al was not affected, since only a subpopulation of basal cells expressed K1 as a result of 8S-LOX transgene expression. We previously reported on the ability of 8-HETE to induce K1 in primary keratinocytes . In the present study, we observed induction of K1 as well as the differentiated cell morphology in MT1/2-8S-LOX stable clones, which also supports a role of 8S-LOX in keratinocyte differentiation. Moreover, the fact that this phenomenon was seen only in early passages of transfected clones and thereafter the transgene expression was lost as cells were passaged suggests an inhibitory effect of 8S-LOX expression on the MT1/2 cell proliferation as well. In fact, loss of transgene expression was also observed in other papilloma cells that were transfected with K1/K10 (Kartasova et al., 1992) , or loricrin genes (Hohl et al., 1991) . It therefore appears that expression of differentiation-related genes in papilloma cells is not compatible with mitotic activity of those cells. In the case of 15S-LOX-2, stable clones of prostate carcinoma cells were initially established; however, the transgene expression was selectively lost starting with passage 3 (Bhatia et al., 2003) . From this point of view, we can speculate on the reason why 8S-LOX is not expressed or induced, in general, in established murine keratinocyte cell lines, unlike in primary keratinocytes. It is likely that complete repression of 8S-LOX would be of benefit to the continuously proliferating cells.
On the other hand, enforced expression of 8S-LOX was sustained much longer in CH72 carcinoma cells compared to that in MT1/2 or 308 papilloma cells. This may be partly because carcinoma cells do not respond to differentiating signals, as others have reported. For example, in the case of K1 or K10 stable transfectants, K1 or K10 expression was compatible with mitotic activity of carcinoma cells, although it was not with that of papilloma cells (Kartasova et al., 1992) . In fact, we could not observe any indication of keratinocyte differentiation such as K1 expression or differentiated cell morphology in CH72-8S-LOX stable clones. Forced expression of 8S-LOX, however, may have inhibited cell proliferation through mechanisms other than induction of differentiation. Although we do not know the exact mechanism yet, considering our data on the effect of exogenous 8-HETE on cell proliferation, it is likely that constitutive production of 8-HETE in CH72-8S-LOX stable clones arrested a subpopulation of the cells at the G1 phase. It is also possible that 8-HETE induced contact inhibition, since we found fewer cells at confluence with the 8S-LOX clones compared to the neo clones. Interestingly, the inhibitory effect of 8S-LOX expression on CH72 cell proliferation was much more pronounced in xenografts. The fact that 8S-LOX expression was not detected in the tumors isolated from the 8S-LOX clone xenografts suggests a possibility of selection against cells expressing 8S-LOX in tumors. In the case of K10 stable transfectants of carcinoma cells, they proliferated in culture while expressing K10; however, the expression was lost in xenografted tumors (Kartasova et al., 1992) . Of note is that the tumor suppressing effect of 8S-LOX clones apparently depends on enzyme activity, because one of the 8S-LOX stable clones that expressed 8S-LOX protein but did not have enzyme activity did not show any significant difference in xenograft tumor growth compared to that of neo clones (data not shown).
Observations that the level of 8S-LOX expression as well as the increased 8-HETE levels in TPA-induced hyperplastic skin and in reversible papillomas, but not in carcinomas (Nair et al., 2000) , have been presented as evidence that 8-HETE is involved in tumor promotion as well as in malignant progression. However, our clear demonstration on the selective expression of 8S-LOX in differentiated regions of normal skin and of tumors strongly suggests the level of 8S-LOX expression is closely correlated with the extent of differentiation (Figure 9 ). Interestingly, this pattern of 8S-LOX expression is very similar to that of K1/K10 expression during mouse skin carcinogenesis. That is, K1 is also strongly expressed in TPA-induced hyperplastic skin and papillomas (Nelson and Slaga, 1982; Toftga˚rd et al., 1985; Huitfeldt et al., 1991) ; however, the expression is reduced during progression of papillomas toward malignancy (Nischt et al., 1988) and is absent in squamous cell carcinomas (Yuspa, 1985) . We suggest that not only does 8S-LOX expression accompany keratinocyte differentiation but also 8S-LOX expression actively participates in inducing keratinocyte differentiation and in inhibiting skin tumorigenesis. Previously reported strong induction of K1 by exogenous 8-HETE treatment of primary keratinocytes supports this active participation of 8S-LOX in keratinocyte differentiation . Conversely, knocking out protein kinase Ceta, Figure 9 Proposed correlation of 8S-LOX expression and differentiation in mouse skin carcinogenesis. A relationship between 8S-LOX expression and the extent of differentiation in normal skin, TPA-treated skin, papillomas, and carcinomas in mice is shown diagrammatically. TPA treatment of mouse skin expands the differentiated compartment of keratinocytes, which is a phenotypic characteristic of hyperplasia. The extent of expansion reaches the highest level in papillomas and starts to reduce as papillomas progress into malignant carcinomas. Since the expression of 8S-LOX has been observed to be confined to the regions of differentiated keratinocytes, it is proposed that the level of 8S-LOX expression accompanies the extent of keratinocyte differentiation during skin tumor development which has been shown to be involved in keratinocyte differentiation, resulted in higher sensitivity to skin carcinogenesis than wild-type mice (Kashiwagi et al., 2002) . In addition, data from several in vitro studies have also shown that suppression of malignancy in tumor-and normal-cell hybrids resulted from restoration of the terminal differentiation program in tumor cells that was imposed by the normal-cell partner (Stanbridge et al., 1982) . From this point of view, although we cannot completely exclude a possibility of other physiological changes resulting from 8S-LOX overexpression in C57BL/6J mouse skin or in tumor cells, most likely increased differentiation conferred by 8-HETE mediates the anticarcinogenic effects of forced 8S-LOX expression.
Although 8S-LOX was cloned as a murine homolog of human 15S-LOX-2 and shares 78% identity in amino-acid composition with human 15S-LOX-2 (Jisaka et al., 1997), their functional homology has been in doubt since their tissue and cellular localization are quite distinctive Jisaka et al., 1997; Shappell et al., 2001b) . In human prostate, specific expression of 15S-LOX-2 was detected in the glandular prostate epithelial cells but not in basal cells or other cell types including stromal cells (Bhatia et al., 2003; Shappell et al., 1999 ). Interestingly, the protein level and enzymatic activity of 15S-LOX-2 have been shown to be downregulated in prostate carcinomas compared with normal and benign prostate tumors (Shappell et al., 1999; Jack et al., 2000) , and this reduced expression was inversely correlated with the degree of tumor differentiation (Jack et al., 2000) . Moreover, exogenous 15-HETE treatment or restoration of 15S-LOX-2 expression in prostate cancer cells inhibits cell proliferation in vitro and in vivo (Bhatia et al., 2003; Tang et al., 2002) . 15-HETE is a ligand of PPARg, which is involved in adipocyte differentiation. In fact, several reports have also shown that these anticarcinogenic and prodifferentiating roles of 15S-LOX-2/15-HETE in prostate are mediated by activation of PPARg (Shappell et al., 2001a; Hsi et al., 2002) . Collectively, these observations are very similar to what we observed with 8S-LOX in mouse skin and skin cancer cells in the present study. Therefore, although the tissues in which 8S-LOX and 15S-LOX-2 are expressed are different, both genes appear to be involved in tissue-specific differentiation as well as to function as a suppressor of tissue-specific tumor development.
In summary, our results demonstrate that the expression of 8S-LOX is closely associated with keratinocyte differentiation and the enforced expression inhibits mouse skin tumorigenesis. This antitumorigenic role of 8S-LOX appears to come from its pleiotrophic effects including differentiation and inhibition of proliferation, either of which would reduce tumorigenesis. Considering its promising contributions to understanding the functional role of human 15S-LOX-2, the mechanisms of tumorigenesis, as well as differentiation, more profound mechanistic studies in the future on the molecular function of 8S-LOX/8-HETE in mouse skin carcinogenesis are required and the studies could lead to novel approaches to the prevention or treatment of human cancers.
Materials and methods
Generation of C57BL/6J transgenic mice overexpressing the 8S-LOX gene
Previously established homozygous loricrin 8S-LOX transgenic mice on the FVB background were backcrossed for six generations onto C57BL/6J mice (Jackson Laboratory, Bar Harbor, MA, USA). All progeny were genotyped for the expression of the 8S-LOX transgene using primers 5 0 -CTCTTCCAGCTCTGTTGTCTCCG-3 0 and 5 0 -GTATGCCCTCCTTGTTGG-3 0 with the following PCR cycling parameters: 941C, 1 min; 39 cycles: 941C, 1 min; 501C, 2 min; 721C, 3 min; one cycle: 941C, 1 min; 501C, 2 min; 721C, 10 min. All of the mice were handled and housed in Association for Assessment and Accreditation of Laboratory Animal Care-accredited facilities and in accordance with USPHS and institutional guidelines.
Two-stage skin carcinogenesis
Groups of twenty 7-week-old female F6 8S-LOX/C57BL/6J transgenic mice or corresponding wild-type littermates were housed four animals/cage and were fed ad libitum under an artificial 12 h day-night cycle. Dorsal skins of the mice were shaved 2 days prior to initiation and only those mice in the resting phase of the hair cycle were used in the tumor experiments. Initiation was accomplished by a single topical application with 200 nmol (50 mg) 7,12-dimethylbenz[a]anthracene (DMBA) under subdued light. At 2 weeks after initiation, the mice were treated with 6.5 nmol (4 mg) of TPA in 200 ml of acetone twice a week for 15 weeks. The mice were then treated with same dose of TPA five times a week for another 14 weeks. The tumor incidence (number of mice bearing tumors/total number of mice) and the tumor multiplicity (number of papillomas/mice) were recorded weekly.
Cell culture
A murine papilloma cell line, MT1/2 (Conti et al., 1988b) , was grown in Eagle's minimal essential medium (EMEM) supplemented with 4% fetal bovine serum (FBS). Stable transfectants of MT1/2 cells were grown in the same media containing 100 mg/ml of G418 (Invitrogen, Carlsbad, CA, USA). CH72 (Conti et al., 1988b) , a murine squamous carcinoma cell line, was grown in EMEM supplemented with 1% FBS. Stable transfectants of CH72 cells were grown in the same media containing 200 mg/ml of G418. Cells were grown in 371C humidified incubator under 5% CO 2
Generation of cell lines stably expressing 8S-LOX
The 2034 bp EcoRI fragment of 8S-LOX cDNA from pGEM3Z.8S-LOX vector was inserted into the corresponding site in a pCI-neo mammalian expression vector (Promega, Madison, WI, USA). The resulting pCIneo.8S-LOX expression vector or pCI-neo empty vector was transfected into the MT1/2 or CH72 cells at 40-50% confluence using FuGENEt6 Transfection Reagent (Roche, Indianapolis, IN, USA) as described by the manufacturer. When cultures were 85% to just confluent, cells were trypsinized and subcultured at a cell density of 2 Â 10 5 cells/ 60 mm dish. G418 (100 and 200 mg/ml for MT1/2 and CH72 cells, respectively) was added to the media at the time of subculture and fresh media with G418 was added every 2-3 days until resistant colonies arose. The colonies were then individually collected or pooled together and expanded into cell lines.
Northern analysis
Total RNA was isolated from cells or tissues using TriReagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's protocol. A total of 10 mg of RNA was separated on a formaldehyde-containing 1% agarose gel, transferred onto nylon membrane (Micron Separation, Westboro, MA, USA), and UV crosslinked onto the membrane with Stratalinker (Stratagene, La Jolla, CA, USA). cDNAs for 8S-LOX, K1, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were labeled with [a-32 P]dCTP (Perkin-Elmer, Boston, MA, USA) by using Random Primed DNA Labeling kit (Roche). Labeled probes were hybridized to the blot using QuickHyb (Stratagene) solution for 2 h at 651C. Blots were washed twice in 2 Â SSC, 0.1% SDS for 15 min at room temperature, and then washed once in 0.1 Â SSC, 0.1% SDS for 40 min at 681C. Specific bands were detected by autoradiography.
Western analysis
Total cellular proteins were separated by 8% SDS-PAGE and transferred onto a polyvinylidene difluoride membrane (Pierce, Rockford, IL, USA). The blot was blocked with 5% nonfat dried milk in 0.1% Tween 20-Tris-buffered saline (TTBS) and probed with antisera against human 15S-LOX-2 (a generous gift from Dr Alan R Brash, Vanderbilt University School of Medicine, Nashville, TN, USA) at 1 : 500 dilution for 1 h at room temperature. This antibody also reacts with murine 8S-LOX (Jisaka et al., 1997) . After washing three times with 0.1% TTBS, the blot was then probed with horseradish peroxidaseconjugated anti-rabbit secondary antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) at 1 : 5000 dilution. The specific bands were detected by an enhanced chemiluminescence kit (Amersham Pharmacia Biotech).
8S-LOX enzyme activity assay
Frozen mouse skin was pulverized and then homogenized with 150 ml of ice-cold phosphate-buffered saline (PBS) buffer containing 0.1% butylated hydroxytoluene (BHT, Sigma Chemical Co., St Louis, MO, USA) and 1 mM EDTA using the ultrasonic sample processor (Misonix Inc., Farmingdale, NY, USA). Subsequently, 8-HETE and 9-HODE were extracted from the homogenates following a modified method of Kempen et al. (2001) . Briefly, aliquots of 1 N citric acid (20 ml) as well as of 2.5 ml of 10% BHT were added to the homogenates and an aliquot (10 ml) of 9(S)-HODE-d4 (100 ng/ ml, Cayman Chemical Co., Ann Arbor, MI, USA) was also added to each sample as an internal standard. Samples were then extracted with 1 ml of hexane : ethyl acetate (1 : 1, v/v) by vortex mixing for 2 min. After centrifugation at 1800 g for 10 min at 41C, the upper organic layer was collected and dried under nitrogen gas. Samples were reconstituted in 100 ml of methanol : 10 mM ammonium acetate buffer, pH 8.5 (70 : 30, v/ v) prior to LC/MS/MS analysis. LC/MS/MS was performed using a Quattro Ultima tandem mass spectrometer (Micromass, Beverly, MA, USA) equipped with an Agilent HP 1100 binary pump HPLC inlet. The protein concentration was determined by the method of Bradford (Bio-Rad, Hercules, CA, USA) and final concentration of 8-HETE and 9-HODE in the tissues were expressed as ng/mg of protein.
CH72-neo or CH72-8S-LOX clones were cultured in 75-cm 2 tissue culture flasks. When cells achieved 70-75% confluency, cells were incubated with 50 mM of AA (Sigma Chemical Co.) for 30 min, 1, and 2 h. The conditioned medium was collected at each time point and subjected to 8-HETE analysis. A measure of 10 ml of 10% BHT was added to 1 ml of the collected medium before application to a Sep-Pak C18 cartridge (Waters Corp., Milford, MA, USA). HETEs were eluted with 1 ml of methanol and dried under a stream of nitrogen. Samples were reconstituted in 200 ml of methanol : 10 mM ammonium acetate buffer, pH 8.5 (70 : 30, v/v) prior to LC/MS/MS analysis. LC/MS/MS was performed under the same conditions as described above. The results were expressed as ng of 8-HETE/5 Â 10 6 cells.
Cell proliferation assays
CH72 cells were plated at a density of 8 Â 10 3 cells/well in 96-well plates. At 24 h after plating, cells were fed with fresh media containing ethanol (vehicle), 1, 5, or 10 mM of 8S-HETE (Cayman Chemical Co., Ann Arbor, MI, USA). Since the volume of the desired amount of 8S-HETE differed from one dose to the other, a compensatory amount of ethanol was included in each experimental group to provide the same volume of vehicle. The cell proliferation rate was determined every 24 h using the CellTiter 96 s Aqueous One Solution Cell Proliferation Assay Kit (Promega), following the manufacturer's protocol. The absorbance was measured at 490 nm using the ELx 800 UV Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT, USA).
CH72-neo and CH72-8S-LOX stable clones were plated at 5 Â 10 4 cells/60 mm dish and were fed with fresh media with G418 every 2 days. At days 1, 3, and 5 after plating, cells were washed twice with PBS and trypsinized with 0.28% trypsin, 0.02% EDTA. Cell numbers were counted with a hemacytometer.
Flow cytometry analysis
CH72 cells were plated in 60 mm dishes (7 Â 10 5 cells/dish) and fed with fresh media containing 0.1% ethanol vehicle, 5, or 10 mM 8S-HETE (Cayman Chemical Co.) at approximately 80% cell confluency. After 24 h of treatment, cells were trypsinized, filtered through a 70 mm mesh, and centrifuged. Cell pellets were then resuspended in PBS and fixed in ethanol on ice for 1 h. Fixed cells were collected by centrifugation and stained with 40 mg/ml of propidium iodide. Single-cell suspensions were then analysed for DNA content using a Coulter EPICS Elite flow cytometer (Beckman Coulter, Miami, FL, USA). DNA histograms were further analysed with MultiCycle software (Phoenix Flow Systems Inc., San Diego, CA, USA) to quantitate the cell cycle phases.
In vivo xenografts
Cultured CH72-neo and CH72-8S-LOX stable clones were trypsinized, centrifuged, and resuspended in PBS at a concentration of 5 Â 10 7 cells/ml PBS. Aliquots (100 ml: 5 Â 10 6 cells) of suspended cells were then subcutaneously injected into each of four different sites (two shoulders and two flanks) of two female athymic nude mice each (Jackson Laboratory). Tumor diameters (length and width) were measured once a week with a caliper for total of 9 weeks and tumor volume was estimated as 1 2 (length Â width 2 ). Mice were killed after 9 weeks, and the tumors were collected for further analyses.
Histological analyses
Dorsal skin or tumors were isolated from mice, fixed in formalin, and processed for paraffin embedding. Tissue sections were stained with hematoxylin and eosin (H&E) and immunostained with antibodies against K1, Ki67, TUNEL or 8S-LOX.
For measuring the rate of epidermal cell proliferation, 100 mg/kg body weight of BrdU (Sigma, St Louis, MO, USA) was injected i.p. into mice 1 h before they were killed. Isolated skin or tumors were fixed in formalin, processed for paraffin embedding and immunostained with anti-BrdU antibody. The number of BrdU-positive cells in the interfollicular epidermis or in the tumors was counted in several random tissue sections from several mice in each experimental group. The labeling index was calculated as the percentage of BrdU-positive basal cells to total number of basal cells in the interfollicular epidermis.
Inter-SSR PCR
Genomic DNA from CH72 stable clones as well as matched xenograft tumors was analysed by the inter-SSR PCR method (Zietkiewicz et al., 1994) using equimolar mixture of (CA) 8 RY, (CA) 8 RG, and (AGC) 4 Y primers (where R ¼ purine, and Y ¼ pyrimidine). Amplifications were carried out in 25 ml reactions containing 50-100 ng of genomic DNA, 2.5 ml 10 Â PCR buffer (15 or 20 mM MgCl 2 ), 2% formamide, 0.2 mM dNTP, and 1 mM primer, using the following cycling parameters: 941C, 3 min; 30 cycles: 941C, 30 s; 541C, 45 s, 721C, 2 min; 721C, 7 min. PCR products were analysed by Sequi-Gen Sequencing Cell (Bio-Rad Laboratories, Hercules, CA, USA) and Criterion pre-cast 10% polyacrylamide gels (BioRad Laboratories). The products were visualized by silver staining (Amersham-Pharmacia Biotech) and with Vistra Green staining (Amersham International, Buckinghamshire, UK).
Statistical analysis
Various statistical tests were conducted using GraphPad InStat 3.0 (GraphPad Software Inc., San Diego, CA, USA) to determine the statistical differences between various experimental groups. A P-value o0.05 was considered statistically significant. Abbreviations AA, arachidonic acid; COX, cyclooxygenase; PG, prostaglandin; LOX, lipoxygenase; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; LA, linoleic acid; TPA, 12-O-tetradecanoylphorbol-13-acetate; PPAR, peroxisome proliferator-activated receptor; K1, keratin 1; DMBA, dimethylbenz[a]anthracene; EMEM, Eagle's minimal essential medium; FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TTBS, Tween 20 Tris-buffered saline; BHT, butylated hydroxytoluene; PBS, phosphatebuffered saline; LC/MS/MS, liquid chromatography/tandem mass spectrometry; H&E, hematoxylin and eosin; TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling; BrdU, 5-bromo-2 0 -deoxyuridine; SSR, simple sequence repeat.
